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uEfficacy of Revascularization for Renal Artery Stenosis Caused by
Fibromuscular Dysplasia: A Systematic Review and Meta-Analysis
Trinquart L, Mounier-Vehier C, Sapoval M, et al. Hypertension 2010;56:
525-32.
Conclusion: Renal artery vascularization in patients with fibromuscu-
lar disease (FMD) by angioplasty or surgery yields moderate benefits, with
significant variation among studies. Blood pressure outcome is strongly
influenced by patient age.
Summary: Surgery and percutaneous renal artery angioplasty are both
used to treat renal artery stenosis. Benefit for revascularization of atheroscle-
rotic renal arteries stenosis is limited (Nordmann AJ, Cochrane Database
Syst Rev 2003:CD002944; Balk E et al, Ann InternMed 2006;145:901-12;
Wheatley K et al, N Engl J Med 2009;361:1953-62). The limited benefit of
revascularization of atherosclerotic renal artery stenosis is thought to reflect
underlying renal parenchymal disease associated with age.However, patients
with FMD are younger (30s and 40s), with normal kidney function. FMD
patients are also primarily women. No randomized control trials and no
comprehensive systematic reviews have assessed blood pressure outcome
with revascularization for renal artery stenosis secondary to FMD. The
primary objective of this systematic review was to assess the rate of hyper-
tension cure after renal artery revascularization in patients with hypertension
and FMD renal artery stenosis. Other objectives were to assess technical
success rates of revascularization, risk of complication, and to explore
variation of outcomes across subgroups. This systematic review includes
studies of both surgical and percutaneous revascularization of FMD renal
artery stenosis.
The authors selected 47 angioplasty studies involving 1660 patients
and 23 surgical studies involving 1014 patients. Using the definition of cure
particular to each study, combined rates of hypertension cure were estimated
to be 46% (95% CI, 40%-52%) after angioplasty and 58% (95% CI, 53%-62%)
after surgery. There was substantial variation across studies. Patient age and
time of publication were negatively associated with the probability of being
“cured.” Cure rates using the current definition of hypertension cure (blood
pressure 140/90 mm Hg, without treatment) were only 36% after angio-
plasty and 54% after surgery, respectively. Risk of periprocedural complica-
tions were 12% after angioplasty and 17% after surgery, with fewer major
complications after angioplasty (6%) vs surgery (15%).
Comment: This is the largest meta-analysis reported on this subject.
Overall, this study found that the probability of cure for revascularization of
renal artery stenosis secondary to FMD was negatively associated with age,
known duration of hypertension, medial-type FMD, time of publication,
and a more strict definition of cure. Future studies of revascularization for
renal artery stenosis should include standardization of the definition of
blood pressure cure using the current criteria of a blood pressure 140/90
mm Hg, without treatment, as the definition of cure. Because only one
patient in three has a normal blood pressure after percutaneous renal artery
revascularization for FMD, with a 12% risk of complications, a randomized
trial comparing percutaneous renal artery angioplasty with medical treat-
ment for FMD should be considered.
Results of Superior Vena Cava Reconstruction With Externally Sup-
ported Polytetrafluorethylene Vascular Prostheses
Okereke IC, Kesler KA, Rieger KM, et al. Ann Thorac Surg 2010;90;383-7.
Conclusion: Superior vena cava (SVC) reconstructions with externally
supported polytetrafluorethylene (PTFE) grafts have low perioperative mor-
tality and high short-term patency.
Summary: SVC obstruction can result in facial swelling, dyspnea, and
stridor. The SVC, depending on individual circumstances, may be recon-
structed with autogenous tissue, stents, or grafts. In this report, the authors
describe experience with SVC reconstruction using externally supported
PTFE grafts. The study spans 1991 to 2002 and was a retrospective review
of medical records of 38 patients with SVC reconstruction with externally
supported PTFE grafts. All but four patients had reconstruction for malig-
nant disease.Mean age was 45 15.8 years, and 77%weremen. The surgical
approach was sternotomy in 27 and thoracotomy in 8, with a clamshell
incision in 3 and a trap-door incision in 1. The technique involved initial
dissection of the tumor or benign surrounding tissue with assessment of the
SVC. The innominate veins and the SVC just proximal to right atrial–SVC
junction were both isolated. The azygous vein was ligated. SVC clamping
was well tolerated hemodynamically. Hemodynamic compromise was easily
stabilized with fluid administration or vasopressor medications. Two pa-
tients with tumors extending to the right atrium required cardiopulmonary
bypass. The most common graft size diameter was 16 mm (range, 8-19
p
Cm). A right innominate vein to SVC graft was done in 18 patients (47%),
left innominate vein to SVC interposition graft in 8 (21%), grafts from the
roximal to distal SVC in 9 (24%), and the remaining 3 patients underwent
-type reconstructions. Graft diameters ranged from 8 to 16 mm when an
solated innominate vein SVC reconstruction was preformed and from 13 to
9 mm when the graft went from the proximal SVC to the distal SVC.
ollow-up averaged 15 months (range, 1-113 months), during which 11
atients (29%) died. At the last follow-up, all patients demonstrated minimal
o no brachiocephalic swelling. Imaging was performed after an average of
4 months (range, 1-113 months) in 20 patients (53%). Postoperative
nticoagulation consisted of aspirin only in all but 2 patients. In patients
ndergoing imaging, only 2 of the 20 demonstrated graft occlusion.
Comment: This series of SVC reconstructions primarily for malignant
isease has technical points worth noting. Warfarin anticoagulation is appar-
ntly not required. Graft occlusion is well tolerated. The authors detail
ethods to avoid graft kinking, particularly with sternotomy closure. Also,
econstruction of only one innominate vein when SVC innominate conflu-
nce is involved provides adequate results. It is technically more difficult to
erform a right innominate vein-to-graft anastomosis then a left innominate
ein anastomosis. However, the right anastomosis results in minimal graft
ngulation and direct blood flow into the right atrium. Sternal retractors
hould be partially closed before creating the second anastomosis in a left
nnominate to SVC reconstruction. Performing both anastomoses with
ternal distraction results in graft kinking with sternotomy closure.
chieving the Goal of the Fistula First Breakthrough Initiative for
revalent Maintenance Hemodialysis Patients
ynch JR, Wasse H, Armistead NC, et al. Am J Kidney Dis 2010;57:78-89.
Conclusions: Achieving the Center for Medicare and Medicaid Ser-
ices (CMS) goal of 66% prevalent arteriovenous fistula (AVF) use is feasible
or individual dialysis facilities. There is a need for decreased regional
ariation in fistula use to fully realize the CMS goal.
Summary: National Kidney Foundation Kidney Disease Outcome
uality Initiative (DOQI) guidelines recommend AVF at onset of hemodi-
lysis (Am J Kidney Dis 2006;48:S176-322). CMS then developed the
istula First Breakthrough Initiative (FFBI) to improve AVF use in the
nited States and collect data on fistula usage. The initial FFBI goal was 40%
revalence of AVFs. Once achieved, CMS established a new goal of 66%
VF use by June 2009. The target 66%was based on the fact AVF prevalence
n Asia and Europe is 60% to 90% (Ethier J, Nephrol Dial Transplant
008;23:3219-26). However, some point out that the end-stage renal
isease (ESRD) population in Asia and Europe may not be similar to that in
he United States. In addition, AVF usage in the United States is measured
or the entire ESRD population. International estimates can be based on
reatment facility samples and may not capture the entire ESRD population.
his led some to question the appropriateness of the 66% CMS goal of AVF
se.
The authors examined patterns of AVF use to assess the potential for
ttaining the CMS goal. This was an observational study involving U.S.
ialysis facilities with a mean patient census of 10 from January 2007 to
pril 2010. The authors tracked mean changes in facility level AVF use and
he percentage of facilities achieving the 66% CMS goal. The data were
erived from 4058 dialysis facilities with a mean patient census of 72  4.
ean prevalent AVF use increased from 45.3% to 55.5% (P  0.001), with
ubstantial variation across regions. During the 40 months of the study,
458 facilities (35.9%) reached the CMS goal at least once. Obtainment of
he goal varied from 22.1% of all treatment facilities in Network 5 (repre-
enting the mid-Atlantic states) to 79.0% in Network 16 (representing the
acific Northwest). The percentage of facilities achieving the goal increased
rom 6.4% to 19% during the 40 months (P .001). Facilities achieving the
MS goal sustained mean AVF use 66% of the time for 12.9  11.9
onths. The variation in proportion of facility patients using an AVF in the
ast measured month was only explained 20% of the time by case mix and
ther facility characteristics, indicating substantial unexplained variability in
se of AVFs.
Comment: The CMS goal of achieving 66% prevalent AVF use is
btainable, but not easily. AVF performances differ vastly in geographically
ontiguous networks. Facilities with higher percentages of white and His-
anic patients, patients with diabetes as a primary cause of ESRD, patients
ith glomerulonephritis as the primary cause of ESRD, and patients begin-
ing long-term hemodialysis therapy tended to have higher AVF use. AVF
se was lower in facilities with higher percentages of women, patients with
eripheral vascular disease starting hemodialysis, and with older populations.
ase mix, however, explains only a proportion of the variation of AVF use,
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June 20111752 Abstractsandmuchwork needs to be done to identify the causes of regional variability.
Finally, it needs to be emphasized that “fistula first” does not mean “fistula
only.” Patients with poor likelihood of maturation of a fistula, or a short life
expectancy, may be better candidates for a graft.
Complex Plaques in the Proximal Descending Aorta: An Underesti-
mated Embolic Source of Stroke
Harloff A, Simon J, Brendecke S, et al. Stroke 2010;41:1145-50.
Conclusion: Retrograde flow from complex descending aorta plaques
is a potential source of emboli to all brain territories.
Summary: Complex aortic plaques are defined as4 mm in thickness,
or those associated with ulceration or that have mobile thrombi. Such
plaques are considered a significant source of stroke. When such plaques are
located in the ascending aorta or the aortic arch, embolization can be
through antegrade flow from the aorta into a major cerebral vessel. How-
ever, the incidence of complex plaques is highest in the proximal descending
aorta. Plaques in this location have only previously been considered a source
of stroke in the setting of severe aortic valve insufficiency resulting in
retrograde flow in the aorta during diastole. However, it now appears that
diastolic retrograde flow in the descending thoracic aorta may be common in
patients with atherosclerosis and therefore serve as a potentially overlooked
mechanism of stroke (Svedlund S, et al, Cerebrovasc Dis 2009;27:22-8).
The authors hypothesize that retrograde flow in the proximal descending
thoracic aorta has the potential to reach all the supra-aortic arteries and, thus,
may be a previously underappreciated source of stroke in the setting of a
complex descending aorta plaque. They studied 94 consecutive acute stroke
patients who had aortic plaques 3 mm in thickness as determined by
transesophageal echocardiography. All subjects underwent magnetic reso-
nance imaging (MRI) to localize complex plaques and to measure time-
resolved 3-dimensional (3D) blood flow within the aorta. The 3D visualiza-
tion was then used to determine if diastolic retrograde flow connected
plaque location with origins of the left subclavian, left common carotid, or
innominate artery. If retrograde flow associated with a complex descending
thoracic aortic plaque reached a supra-aortic vessel that supplied the territory
of anMRI-determined acute embolic retinal or cerebral infarction, the distal
thoracic aortic plaque was considered a possible embolic source for the
stroke.
Decreasing heart rate was correlated with increasing flow reversal to the
aortic arch (P  .02). Retrograde flow associated with complex proximal
descending aortic plaques reached the left subclavian artery in 58.5% of
cases, the left common carotid artery in 24.5%, and the brachiocephalic
artery in 13.8%. Stroke etiology was determined in 57 of the 94 patients in
the study and was not determined in the remaining 37 patients, so-called
cryptogenic stroke. Potential embolization from a descending thoracic
aortic plaque was identified in 19 of 57 patients (33.3%) with a determined
stroke and in 9 of 37 patients (24.3%) with cryptogenic stroke.
Comment: The authors’ data suggest that plaques in the descending
thoracic aorta beyond the origins of the great vessels should also be consid-
ered a source of stroke. Flow reversal over complex descending thoracic
aortic plaques can potentially reach all supra-aortic arteries. Descending
thoracic aortic plaques should be therefore assessed in all patients with
cryptogenic stroke as a possible source of the stroke. The authors found an
8% incidence of complex descending thoracic aortic plaques in patients with
determined stroke and 28% in patients with cryptogenic stroke. Retrograde
flow was not correlated with aortic valve insufficiency. These observations
clearly contradict previous beliefs that flow reversal in the descending aorta
is rare and only present in patients with aortic valve insufficiency. The study
demonstrates for the first time that the proximal descending aorta is a
potential source for embolic stroke in all brain territories.
Effectiveness of a Smoking Cessation Program for Peripheral Artery
Disease Patients: A Randomized Controlled Trial
Hennrikus D, Joseph AM, Lando HA, et al. J Am Coll Cardiol 2010;56:
2105-12.
Conclusions: Many long-term smokers with peripheral artery disease
(PAD) are willing to engage in an intensive smoking cessation program. A
smoking cessation programwith intensive intervention is more effective than
minimal care.
Summary:Only one randomized trial has evaluated the effectiveness of
smoking cessation programs. This trial (Gavin K, et al, Int J Nurs Stud
2001;38:91-105) evaluated the effectiveness of a nurse-conducted smoking
cessation education program using nicotine gum. There was a difference
between the intervention and control group’s self-reported number of
cigarettes smoked. However, biomarkers of tobacco use (urinary cotinine
and expired carbon monoxide) provided conflicting results with the self-
reported number of cigarettes smoked. Given that cigarette smoking is the
most important risk factor for development of progression of PAD, the
current study was designed to test the effectiveness of an intensive smoking
cessation program in patients with PAD. The authors first sought to deter-
M
Cine whether PAD patients were willing to enroll in such a program. The
econd objective was to examine the effectiveness of the program.
Participants, who were recruited as outpatients, were identified as
aving lower extremity PAD frommedical records andwere also identified as
igarette smokers. They were randomly assigned to minimal intervention or
n intensive tailored PAD-specific counseling intervention. Surveys were
ompleted at baseline and at 3 and 6 months. Reported 7-day prevalent
moking abstinence was confirmed by carbon monoxide or cotinine levels.
f 687 outpatients identified as probable smokers with lower extremity
AD, 232 met eligibility requirements for this study and 124 (53% of those
ligible) enrolled in the study. Participants were receptive to counseling.
hey received a median of 8.5 counseling sessions (range, 0-18). Those
articipants who had been assigned to the intensive intervention group were
ore likely to have confirmed abstinence from cigarette smoking at the
-month follow-up: 21.3% in the intensive group vs 6.8% in the minimal
ntervention group (2  5.21; P  .023).
Comment:Many patients with PAD who are smokers are interested in
uitting and are receptive to a formal smoking cessation program. Those
ho chose to participate in the study almost universally indicated an under-
tanding of the health risks of smoking. There was a high desire to quit
igarette smoking, as evidenced by the high level of engagement in the
ounseling sessions by those assigned to intensive intervention. The partic-
pants in this study were highly motivated to quit, but only about one-fifth of
hose in the intensive intervention group were able to quit. The study
ndicates the importance of more intensive intervention in achieving absti-
ence from cigarette smoking. Perhaps most importantly, it points out the
est we have to offer to achieve smoking cessation is still woefully inade-
uate, even for motivated patients.
ormal CSF Ferritin Levels in MS Suggest Against Etiologic Role of
hronic Venous Insufficiency
orthington V, Killestein J, Eikelenboom MJ, et al. Neurology 2010;75:
617-22.
Conclusion: Cerebral spinal fluid (CSF) ferritin levels do not support
n etiologic role for chronic cerebral spinal venous insufficiency (CCSVI)–
elated parenchymal iron deposition in multiple sclerosis (MS).
Summary: A new and controversial hypothesis suggests disease pro-
ression in MS may be related to CCSVI and the resulting toxic effects of
arenchymal iron deposition in the central nervous system (CNS; Singh AV,
amboni P, J Cereb Blood Flow Metab 2009;29:1867-78). When iron is
resent in the CNS, it simulates intrathecal expression of ferritin (Keirg et al,
lin Chim Acta 1993;216:153-66). An indirect test for deposition of iron in
he CNS is quantification of ferritin. The authors postulated that if CSSVI
eads to parenchymal iron deposition in MS, there ought to be increased
SF ferritin levels. They quantified CSF ferritin levels from a previously
ublished cohort with clinically definite MS (Petzold A, et al, Brain 2002;
5:1462-473; Polman CH, et al, Ann Neurol 2005;58:840-6). The current
tudy consisted of a cross-sectional and a longitudinal component. In the
ross-sectional part of the study, CSF ferritin levels in patients with MS were
ompared with levels in patients with subarachnoid hemorrhage and occult
leeding (siderosis). An inflammatory neurologic control group was also
ncluded because CSF ferritin is known to increase inflammation. The
ypothesis was that if CCSVI-related parenchymal iron deposition is a major
athologic feature of MS, CSF ferritin levels in MS patients should be in the
ange seen with those with subarachnoid hemorrhage or inflammation. In
he longitudinal component of this study, each patient with MS was his or
er own control. The hypothesis was that ongoing parenchymal iron depo-
ition due to CCSVI should lead to an increase CSF ferritin over time. A final
nalysis was to determine whether CSF ferritin was related to MS progres-
ion, as detected on brain magnetic resonance imaging or clinically.
The cross-sectional component of the study included 1408 patients
nd the longitudinal component included 29 patients. The definition of
athologic CSF ferritin levels was 12 ng/mL. This level was observed in
% of the control patients (median, 4 ng/mL), in 91% of those with
uperficial siderosis (75 ng/mL), in 73% with a subarachnoid hemorrhage
59 ng/mL), in 10% with relapsing-remitting MS (5 ng/mL), in 11% with
rimary progressive MS (6 ng/mL), in 23% with secondary progressive MS
5 ng/mL), and in 23% with meningoencephalitis (5 ng/mL). In the MS
atients monitored longitudinally, there was no change in CSF ferritin levels
uring the 3-year follow-up period and there was no correlation of follow-up
SF ferritin levels with changes in clinical or brain MRI parameters of MS.
Comment: These data do not support the CCSVI hypothesis for MS.
he authors, however, point out a number of short-comings of their study,
ncluding that ferritin is only an indirect marker for CSF iron deposition and
hat they have no longitudinal data on CSF ferritin levels in the control
atients. This precludes conclusions about variations over time of individual
SF ferritin levels in an assumed normal population. Also, with respect to
RI, they do not have T2 imaging data potentially permitting correlation of
SF ferritin levels with parenchymal iron deposition or markers of CCSVI.
